Hedera Dx Hedera Profiling 2 ctDNA Test Panel

Hedera Dx has launched the blood-based Hedera Profiling 2 ctDNA Test Panel for precision cancer therapy guidance. The product is a combination of laboratory reagents and interpretation software to enable assays covering over 80 percent of the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) Level I genes. The Hedera Prime software platform is IVD registered and can rapidly interpret DNA sequencing results and generate clinical reports, the company said.